ABSTRACT
Objective To compare the clinical effects and safety of rosiglitazon and glimepiride separately combined with insulin in the treatment of patients with T2DM for first diagnosed.Methods 150 patients with T2DM for first diagnosed were chosen and randomly divided into two groups according to digital table,including rosiglitazon group (60 patients) with rosiglitazon,and glimepiride group (60 patients) with glimepiride on the basis of glargine insulin.The compliance time of blood glucose,the insulin used doses,the levels of BMI,FBG,2hFBG,HbA1 c,FC-P,2hC-P,HOMA-IR and HOMA-islet before and after treatment and hypoglycemia incidence of both two groups were compared.Results There were no statistically significant differences in the compliance time of blood glucose and the insulin used doses between 2 groups (P ＞ 0.05).The levels of BMI before and after treatment of the glimepiride group were (25.03 ± 3.25) kg/m2,(27.42 ± 3.49) kg/m2,respectively,which of the rosiglitazon group were (24.71 ± 3.18) kg/m2,(24.80 ± 3.30) kg/m2,respectively.The BMI after treatment of the glimepiride group was significantly lower than that of the rosiglitazon group (t =3.37,P ＜ 0.05).There were no statistically significant differences in the levels of FBG,2hFBG,HbAlc,FC-P,2hC-P,HOMA-IR and HOMA-islet between the two groups(all P ＞ 0.05).The incidence rates of hypoglycemia in the rosiglitazon group and glimepiride group were 14.67％,2.67％,respectively.The incidence rate of hypoglycemia of the glimepiride group was significantly lower than that of the rosiglitazon group (x2 =7.15,P ＜ 0.05).Conclusion Rosiglitazon and glimepiride separately combined with insulin in the treatment of patients with T2DM for first diagnosed possess the same clinical effects in controlling the blood glucose levels and improving the islet function;and glimepiride application can efficiently prevent the weight gain amount and hypoglycemia.